Dashboard
Manage Tickers

TNGXTango Therapeutics, Inc.

Nasdaq tangotx.com


$ 10.94 $ -0.90 (-7.61 %)    

Tuesday, 03-Sep-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 461.29 $ -14.46 (-3.04 %)
DIA $ 410.26 $ -5.96 (-1.43 %)
SPY $ 551.70 $ -11.60 (-2.06 %)
TLT $ 97.57 $ 1.26 (1.31 %)
GLD $ 230.29 $ -1.00 (-0.43 %)
$ 10.93
$ 11.64
$ 10.92 x 168
-- x --
$ 10.90 - $ 11.66
$ 5.15 - $ 13.03
534,583
na
1.17B
$ 0.86
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2024 06-30-2024 10-Q
2 05-08-2024 03-31-2024 10-Q
3 03-18-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-27-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-10-2022 06-30-2022 10-Q
10 05-11-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-14-2021 03-31-2021 10-Q
15 03-31-2021 12-31-2020 10-K
16 11-13-2020 09-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

analyst-expectations-for-tango-therapeuticss-future
Analyst Expectations For Tango Therapeutic...
08/08/2024 14:00:49

wedbush-maintains-outperform-on-tango-therapeutics-raises-price-target-to-13
Wedbush Maintains Outperform on Tango Ther...
08/08/2024 13:31:20

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and raises the price target fro...

tango-therapeutics-shares-are-trading-higher-after-the-company-reported-better-than-expected-q2-financial-results
Tango Therapeutics shares are trading high...
08/07/2024 13:06:10

tango-therapeutics-cash-balance-of-322m-as-of-june-30-is-expected-to-provide-cash-runway-into-2027
Tango Therapeutics' Cash Balance Of $322M ...
08/07/2024 11:26:20

tango-therapeutics-q2-2024-gaap-eps-024-beats-033-estimate-sales-19875m-beat-7423m-estimate
Tango Therapeutics Q2 2024 GAAP EPS $(0.24...
08/07/2024 11:25:29

jefferies-initiates-coverage-on-tango-therapeutics-with-buy-rating-announces-price-target-of-19
Jefferies Initiates Coverage On Tango Ther...
07/17/2024 12:45:41

Jefferies analyst Maury Raycroft initiates coverage on Tango Therapeutics (NASDAQ:TNGX) with a Buy rating and announces Pric...

cantor-fitzgerald-reiterates-overweight-on-tango-therapeutics
Cantor Fitzgerald Reiterates Overweight on...
07/09/2024 13:18:53

Cantor Fitzgerald analyst Eric Schmidt reiterates Tango Therapeutics (NASDAQ:TNGX) with a Overweight.

expert-outlook-tango-therapeutics-through-the-eyes-of-6-analysts
Expert Outlook: Tango Therapeutics Through...
07/09/2024 13:00:12

hc-wainwright--co-reiterates-buy-on-tango-therapeutics-maintains-13-price-target
HC Wainwright & Co. Reiterates Buy on Tang...
07/09/2024 10:43:12

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $13 price ...

Core News & Articles
CORRECTION: Tectonic Therapeutic Ticker Is...
06/26/2024 19:04:33

hc-wainwright--co-maintains-buy-on-tango-therapeutics-lowers-price-target-to-13
HC Wainwright & Co. Maintains Buy on Tango...
05/28/2024 10:41:16

HC Wainwright & Co. analyst Robert Burns maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price targ...

guggenheim-maintains-buy-on-tango-therapeutics-lowers-price-target-to-14
Guggenheim Maintains Buy on Tango Therapeu...
05/24/2024 16:31:14

Guggenheim analyst Charles Zhu maintains Tango Therapeutics (NASDAQ:TNGX) with a Buy and lowers the price target from $16 to...

forecasting-the-future-4-analyst-projections-for-tango-therapeutics
Forecasting The Future: 4 Analyst Projecti...
05/24/2024 15:01:25

barclays-maintains-overweight-on-tango-therapeutics-lowers-price-target-to-13
Barclays Maintains Overweight on Tango The...
05/24/2024 14:56:22

Barclays analyst Peter Lawson maintains Tango Therapeutics (NASDAQ:TNGX) with a Overweight and lowers the price target from ...

tango-therapeutics-shuts-early-stage-cancer-study-due-to-liver-toxicity
Tango Therapeutics Shuts Early-Stage Cance...
05/23/2024 16:53:11

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now...

wedbush-maintains-outperform-on-tango-therapeutics-lowers-price-target-to-11
Wedbush Maintains Outperform on Tango Ther...
05/23/2024 16:35:58

Wedbush analyst Robert Driscoll maintains Tango Therapeutics (NASDAQ:TNGX) with a Outperform and lowers the price target fro...

12-health-care-stocks-moving-in-thursdays-pre-market-session
12 Health Care Stocks Moving In Thursday's...
05/23/2024 12:06:48

tango-therapeutics-shares-are-trading-lower-after-the-company-announced-the-discontinuation-of-its-tng348-program
Tango Therapeutics shares are trading lowe...
05/23/2024 11:02:42

tango-therapeutics-reports-discontinuation-of-tng348-program-says-grade-34-liver-function-abnormalities-were-observed-in-patients-remaining-on-study-longer-than-eight-weeks
Tango Therapeutics Reports Discontinuation...
05/23/2024 11:01:44

TNG348 was being studied in a phase 1/2 clinical trial evaluating safety, pharmacokinetics, pharmacodynamics and efficacy as a ...

hc-wainwright--co-reiterates-buy-on-tango-therapeutics-maintains-17-price-target
HC Wainwright & Co. Reiterates Buy on Tang...
05/09/2024 11:16:18

HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $17 price ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION